Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Plavix "Irreparable Harm" Debated During Preliminary Injunction Appeal

This article was originally published in The Pink Sheet Daily

Executive Summary

Patent litigation case between Sanofi/Bristol and Apotex will follow in January.

You may also be interested in...



Sanofi/Bristol Score Another Victory Over Apotex In Plavix Dispute

Generic drug maker is thwarted in latest attempt to resume clopidogrel sales.

Sanofi/Bristol Score Another Victory Over Apotex In Plavix Dispute

Generic drug maker is thwarted in latest attempt to resume clopidogrel sales.

Generic Plavix Supply Is Dwindling, McKesson Says

Wholesaler forecasts little additional sales of clopidogrel through the remainder of the year.

Related Content

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel